Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 76 to 90 of 123 results for nivolumab

  1. Nivolumab in combination for treating hormone-relapsed metastatic prostate cancer before chemotherapy [ID1619]

    Discontinued [GID-TA10490]

    Technology appraisal guidance
    Discontinued

  2. Nivolumab with ipilimumab for adjuvant treatment of completely resected stage III or IV melanoma [ID1610]

    Discontinued [GID-TA10499]

    Technology appraisal guidance
    Discontinued

  3. Nivolumab in combination with platinum-doublet chemotherapy for untreated non-small-cell lung cancer [ID1135]

    Discontinued [GID-TA10233]

    Technology appraisal guidance
    Discontinued

  4. Nivolumab with ipilimumab for neoadjuvant treatment of early non-small-cell lung cancer [ID3756]

    Discontinued [GID-TA10631]

    Technology appraisal guidance
    Discontinued

  5. Nivolumab with ipilimumab for untreated recurrent or metastatic squamous cell cancer of the head and neck cancer [ID1429]

    Discontinued [GID-TA10512]

    Technology appraisal guidance
    Discontinued

  6. Nivolumab with ipilimumab for untreated PD-L1 mutation-positive non-small-cell lung cancer [ID1675]

    Discontinued [GID-TA10585]

    Technology appraisal guidance
    Discontinued

  7. Nivolumab for treating relapsed or refractory diffuse large B-cell lymphoma [ID986]

    Discontinued [GID-TA10140]

    Technology appraisal guidance
    Discontinued

  8. Relatlimab with nivolumab for treating advanced malignant melanoma after immunotherapy in people over 12 [ID1612]

    Discontinued [GID-TA10484]

    Technology appraisal guidance
    Discontinued

  9. Nivolumab for previously treated gastric or gastro-oesophageal junction cancer [ID1118]

    Discontinued [GID-TA10151]

    Technology appraisal guidance
    Discontinued

  10. Nivolumab for maintenance treatment of extensive stage small-cell lung cancer after chemotherapy [ID1264]

    Discontinued [GID-TA10365]

    Technology appraisal guidance
    Discontinued

  11. Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma (TA414)

    Evidence-based recommendations on cobimetinib (Cotellic) with vemurafenib (Zelboraf) for treating unresectable or metastatic melanoma in adults with a BRAF V600 mutation.

    Technology appraisal guidance
    Published
    26 October 2016
    View recommendations

    Sections for TA414

  12. Nivolumab with ipilimumab for previously treated extensive stage small-cell lung cancer [ID1228]

    Discontinued [GID-TA10203]

    Technology appraisal guidance
    Discontinued

  13. Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma after autologous stem cell transplant [ID1103]

    Discontinued [GID-TA10144]

    Technology appraisal guidance
    Discontinued

  14. Nivolumab for neoadjuvant and adjuvant treatment of localised renal cell carcinoma [ID4047]

    Discontinued [GID-TA10927]

    Technology appraisal guidance
    Discontinued

  15. Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma (TA562)

    Evidence-based recommendations on encorafenib (Braftovi) with binimetinib (Mektovi) for treating unresectable or metastatic BRAF V600 mutation-positive melanoma in adults.

    Technology appraisal guidance
    Published
    27 February 2019
    View recommendations

    Sections for TA562